Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents.

Conflict of interest disclosures for clinical practice guidelines in the national guideline clearinghouse. PLoS One (2012) 1.43

Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol (2008) 1.33

Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures. PLoS Med (2012) 1.09

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study. BMC Med Ethics (2012) 1.03

Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals. Neth Heart J (2012) 0.97

The unbearable lightness of health science reporting: a week examining Italian print media. PLoS One (2010) 0.83

Conflicts of interest among authors of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. PLoS One (2013) 0.81

Disclosures of funding sources and conflicts of interest in published HIV/AIDS research conducted in developing countries. J Med Ethics (2010) 0.81

Disclosure of funding sources and conflicts of interest in phase III surgical trials: survey of ten general surgery journals. World J Surg (2014) 0.76

Reporting funding source or conflict of interest in abstracts of randomized controlled trials, no evidence of a large impact on general practitioners' confidence in conclusions, a three-arm randomized controlled trial. BMC Med (2014) 0.76

Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase. BMC Health Serv Res (2016) 0.75

A Quantitative Analysis of Undisclosed Conflicts of Interest in Pharmacology Textbooks. PLoS One (2015) 0.75

Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08

Financial anatomy of biomedical research. JAMA (2005) 7.49

A national survey of physician-industry relationships. N Engl J Med (2007) 6.63

Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA (2006) 6.48

Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA (2005) 4.58

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42

Editorials and conflicts of interest. N Engl J Med (1996) 3.62

Does declaration of competing interests affect readers' perceptions? A randomised trial. BMJ (2002) 3.44

Protecting subjects, preserving trust, promoting progress I: policy and guidelines for the oversight of individual financial interests in human subjects research. Acad Med (2003) 3.25

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry (2005) 3.05

Declaring financial competing interests: survey of five general medical journals. BMJ (2001) 2.37

Potential research participants' views regarding researcher and institutional financial conflicts of interest. J Med Ethics (2004) 2.32

Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med (2006) 2.29

Conflict of Interest Disclosure Policies and Practices in Peer-reviewed Biomedical Journals. J Gen Intern Med (2006) 2.03

Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial. BMJ (2004) 1.84

Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol (2007) 1.76

Conflict of interest policies in science and medical journals: editorial practices and author disclosures. Sci Eng Ethics (2001) 1.69

The influence of money on medical science. JAMA (2006) 1.68

Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. J Gen Intern Med (2006) 1.63

A new JCI conflict-of-interest policy. J Clin Invest (2007) 1.61

Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants. Acad Med (2006) 1.43

Financial interest and its disclosure in scientific publications. JAMA (1998) 1.42

Full disclosure and the funding of biomedical research. N Engl J Med (2008) 1.38

Sponsorship, authorship, and accountability. JAMA (2001) 1.22

Debating the risks of drug-eluting stents. N Engl J Med (2007) 1.15

Disclosure of financial competing interests in randomised controlled trials: cross sectional review. BMJ (2003) 1.08

Developing model language for disclosing financial interests to potential clinical research participants. IRB (2007) 1.03

Journal policies on conflict of interest: if this is the therapy, what's the disease? Psychother Psychosom (2001) 0.96

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00

Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol (2007) 10.19

The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation (2007) 6.78

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36

Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA (2005) 5.93

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol (2002) 4.64

Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol (2010) 4.50

What clinicians should know about the QT interval. JAMA (2003) 4.45

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Compliance with results reporting at ClinicalTrials.gov. N Engl J Med (2015) 4.17

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation (2006) 3.96

Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83

ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation (2002) 3.80

Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79

MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol (2009) 3.72

Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med (2004) 3.64

Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62

Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58

Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol (2009) 3.54

Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA (2005) 3.51

Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting. Hepatology (2014) 3.40

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol (2011) 3.37

Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35

Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34

Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol (2003) 3.31

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24

Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18

Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol (2010) 3.16

Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming. Cell (2013) 3.13

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J (2008) 3.02

Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01

Cost of cancer care: issues and implications. J Clin Oncol (2007) 3.00

The role of academic health science systems in the transformation of medicine. Lancet (2009) 2.98

Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA (2008) 2.96

Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA (2006) 2.92

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA (2004) 2.89

Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med (2013) 2.86

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation (2005) 2.86

Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83

Variants modulating the expression of a chromosome domain encompassing PLAG1 influence bovine stature. Nat Genet (2011) 2.81

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA (2007) 2.75

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.72

Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol (2012) 2.72

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol (2011) 2.71

Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail (2008) 2.69

Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA (2010) 2.68

Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med (2008) 2.65

The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science (2014) 2.63

Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2009) 2.58

Lessons learned from recent cardiovascular clinical trials: Part I. Circulation (2002) 2.57

Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol (2008) 2.55

Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. Circulation (2011) 2.52

Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49

Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47

International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA (2004) 2.46

Randomized clinical trials--removing unnecessary obstacles. N Engl J Med (2013) 2.43

Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet (2009) 2.40

Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail (2007) 2.39

Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium. Acad Med (2010) 2.38

2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol (2011) 2.37

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31

Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med (2010) 2.28

Economic return of clinical trials performed under the pediatric exclusivity program. JAMA (2007) 2.28

Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days. Am J Manag Care (2011) 2.27

Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. J Gen Intern Med (2005) 2.25

Changing gender prevalence of stone disease. J Urol (2007) 2.25